Member Info for CHELSEA7

And that is something i don"t think has really been discussed here that much. I just wonder what financial commitment we can put on BioNTech with the collaboration, and further as we develop Moditope we come as an intrinsic package to the whole group. They certainly have the financial backing to make this mutually work so well, and like the Grand Challenge Final, it is amazing how far we have come.

11.07. Exactly my thoughts.

Very much so. The subject matter our team is working on, will only gather pace and research after whoever wins the Prize money. Just all down to timing and hopefully, importantly having the funds to take our Platforms further, without the need for more dilution. Question i ask myself is can i see inflection points this coming year, well they haven"t really started yet, have they.

That"s why i asked. Certainly not in stone.

That coupled with the Karolinska extension, and Biontechs added interest in MODI 2, does make me feel we are producing significant data, to allow us to have hopes of a commercial deal in place by 2020.

Morning Crumbs, where did the suggestion that there would be just one outright winner this year, come from.?

Anybody know what upcoming conferences, presentations there are? Thanks

Oh dear...............................11 recs already!!!!

ratcliffewriter
Posts: 8,119
Opinion: No Opinion
Price: 1.35
RE: To allToday 13:37I took your advice and reread the RNS extract quoted by Noise - The more carefully you read, the less you find it says, and it most certainly does NOT say that it works. It reads like a standard video waffle from GM. Let's look a bit closer at it - "The VAL201 compound has demonstrated consistent high safety and tolerability(so does a glass of water), and signs of efficacy ("signs of" - is that overwhelming efficacy or just 'signs', like the odd hint?) throughout its clinical study. A preliminary inspection of the clinical data derived from the original dosing regimen has been completed (so a PRELIMINARY inspection - that's not enough to draw any valid conclusion from) regarding all the subjects that have been treated to date. This inspection considered all dosing regimens (..so?). In summary, our preliminary observations highlight a dose-related impact (Looking for the word 'significant' or 'substantial' or even 'therapeutically relevant' - but can't see it) on patients' physiology and chemistry, such as androgen PSA and various cell and protein turnover factors, which are important in the treatment of cancer (thanks for that - typical GM tag-on statement - irrelevant and patronising). These are in line with anticipated outcomes as far as cancer reduction is concerned."
Many years ago I had a 250 Yamaha that had its engine intact and looked clean, no leaks and the tyres were pumped up. There were no adverse effects from sitting on it and it felt complete. What you might call decent safety and tolerability. When I tried to start it, I turned on the fuel and ignition and kicked the kick starter and it showed ‘signs’ of firing up (you could call that a dose related impact). All afternoon it showed ‘signs’ of firing up, and even ran for a few seconds now and then before cutting out. It burnt small amounts of fuel, and the exhausts got slightly warm occasionally, 'which are important in the running of an engine', to corrupt a phrase. The intermittent ignition, even for a few seconds, was in line with the anticipated outcomes as far as getting it running were concerned. But that was all it did. Eventually I put it up for sale. I had six replies from the small ad in the newsagent’s window, but none of them showed any interest after a short conversation or quick visit, although two did want to come at the same time so I had to ask them to arrive at different times – a bit of competition felt nice, but didn’t alter the reality. Nobody wanted it because it didn’t work anywhere near properly. It ended up in the canal.
Reply | Recommend 11 | Report

Another Ratty classic,

Mathsprof, known you for some years now, I don"t believe for a second you believe that. Anyway, GL, as they say

I agree.

It is very rare to see your posts removed, you manage to keep them as polite as possible.

I said last January, that i could see VAL being taken private by one of their associated companies, for peanuts, (hence the lack of ii or Director Holdings). Haven"t changed my mind one bit.

I had six posts removed Monday, for asking pertinent questions, whilst the blatant ramps were left alone. The likes of fourteen should realise by phoning admin every five minutes just brings their focus to here, and in defence of them they don"t nor can"t research every company that is posted on.

Thats why i gave up my Premium membership this week, and very soon will leave these BBs. How can you get posts removed for asking questions, on a discussion board, where the rampers wont discuss anything but report posts. ???

As it goes my posts can get a bit feisty, but what is posted here is IMHO taking the p..s.

The funniest thing is fourteen warning us of a warning!!!! Lol.

Enjoy your weekends

That is true fourteen, I had your post removed for suggesting there is some kind of insider information the BOD will tell you if you phone them.

Be very careful with these we"s and innuendos

"""we have never said we are happy to lose money"""

Who is the Royal WE?? The same 6/7 rampers who post incessantly here??

Buys 17k

Sells 20k

Thanks.

As it goes fourteen, for once i nearly agree with you.

As one word out of place could be very costly, why do you refer posters to the BOD for a phone chat telling them they will get the true picture?

"""I think people need to understand that while negotiations are on going the BOD have to keep silent on whats going on...one slip..one word out of place and all talks would break down.....imagine how they feel knowing what they have could be worth billions....but have to keep quiet. Its just a matter of time. GL"""

They must be thinking, damn wish i had bought a share!!!.

Delete, far from it. IMHO it will gain momentum

Cont): The academic-biotech-clinical partnerships in this application are really unique, the different perspectives that each discipline brings makes this team’s proposal comprehensive, innovative and therefore very powerful.

Professor Rene Bernards, Grand Challenge Advisory Panel

Just casting my eye on Scancells team. Does this sound like something that will just gain momentum, in the aftermath of results????

LD.......We are thrilled to be on Cancer Research UK's Grand Challenge shortlist: this brings us one step closer to delivering a cancer vaccine template. We believe this approach will facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space.

Professor Lindy Durrant, Principal Investigator

Background
In recent years, therapies that are designed to boost our body’s immune system have revolutionised the treatment of cancer. However, these treatments don’t work in all patients, or against all cancers. That’s because right now we don’t completely understand how different parts of the immune system work together and interact with tumour cells. Currently available immune-boosting therapies – known as ‘cancer vaccines’ – are only targeting a small number of molecules on the surface of tumours, often only triggering a weak response by our immune system.

Professor Lindy Durrant and her team of scientists from the UK, the Netherlands, Germany, and the USA believe that there is a far greater repertoire of molecules that could be targets for cancer vaccines waiting to be discovered. Using the latest vaccination technology, the team believe that they can design cancer vaccines that achieve a much better immune response in significantly more patients.

By not focusing on a single molecule or type of cancer but rather exploring the full spectrum of molecules and combination of molecules capable of inducing specific anti-tumour responses, this Grand Challenge project aims to build templates for how to treat different cancers, with the hope that eventually cancer patients will be offered a vaccine that is specifically designed for their unique tumour.

The Research
In a project spanning four countries, across two different continents, Professor Durrant’s team aim to develop a better understanding of molecules on the surface of tumours – known as ‘tumour antigens’ – that could be targets for treatments. The team will screen huge numbers of these tumour antigens and use machine learning tools to predict which of these would trigger a good immune response in individual patients with cancer. Alongside this, the team will be testing a variety of ways of delivering the treatment to make sure that their vaccine gets to the tumour as efficiently as possible.

Armed with this knowledge, the team will then test their ideas in investigator-initiated clinical studies – with a special focus on patients with head and neck cancer, pancreatic cancer, lung cancer and one type of brain tumour. This will provide crucial missing pieces of the puzzle as to how personalised cancer vaccines can impact patients.

Far from it